For example, Ataluren, a small-molecule compound, is now approved by the European Medicine Agency to treat male patients with Duchenne muscular dystrophy, a disease caused by non-sense mutations in the dystrophin gene (73, 74). Here, DMD is linked to Duchenne muscular dystrophy.